RESUMEN
BACKGROUND: The use of enteral nutrients plays a highly important role in accurate nutrition management, but limited information is currently available on the cautionary points of semi-solid enteral nutrients. AIM: In this study, we examined whether the pharmacokinetic profiles of sodium valproate (SVA), levetiracetam (LEV), and carbamazepine (CBZ) are affected by altering the dosing time of RACOL®-NF Semi Solid for Enteral Use (RASS), a prescribed semi-solid formula. We also investigated whether the pharmacokinetic interaction observed in this study can be avoided by staggered dosing of the chemical drug and semi-solid enteral nutrient. METHODS: The plasma concentration of SVA, LEV and CBZ after oral administration was measured by LC-MS/MS method. RESULTS: There was no difference in pharmacokinetic characteristics of SVA and LEV when the dosing time of RASS was altered. On the other hand, the plasma concentration of CBZ after oral administration at all sampling points decreased with the extension of the dosing time of RASS, which was consistent with the Cmax and AUC. However, no significant difference was observed in the pharmacokinetic profiles or parameters of CBZ between the short-term and long-term RASS dosing groups by prolonging the administered interval of CBZ and RASS for 2 hr. CONCLUSION: We concluded that the pharmacokinetic profiles of CBZ, but not SVA and LEV, after its oral administration are affected by the dosing time of RASS, but staggered administration of CBZ and RASS prevented their interaction.
Asunto(s)
Anticonvulsivantes/farmacocinética , Nutrientes/química , Administración Oral , Animales , Anticonvulsivantes/sangre , Anticonvulsivantes/química , Área Bajo la Curva , Carbamazepina/sangre , Carbamazepina/química , Carbamazepina/farmacocinética , Cromatografía Líquida de Alta Presión , Composición de Medicamentos/métodos , Semivida , Levetiracetam/sangre , Levetiracetam/química , Levetiracetam/farmacocinética , Curva ROC , Ratas , Ratas Sprague-Dawley , Espectrometría de Masas en Tándem , Ácido Valproico/sangre , Ácido Valproico/química , Ácido Valproico/farmacocinéticaRESUMEN
The resolution of halogenated mandelic acids using levetiracetam (LEV) as a resolving agent via forming enantiospecific co-crystal was presented. Five halogenated mandelic acids, 2-chloromandelic acid (2-ClMA), 3-chloromandelic acid (3-ClMA), 4-chloromandelic acid (4-ClMA), 4-bromomandelic acid (4-BrMA), and 4-fluoromandelic acid (4-FMA), were selected as racemic compounds. The effects of the equilibrium time, molar ratio of the resolving agent to racemate, amount of solvent, and crystallization temperature on resolution performance were investigated. Under the optimal conditions, the resolution efficiency reached up to 94% and the enantiomeric excess (%e.e.) of (R)-3-chloromandelic acid was 63%e.e. All five halogenated mandelic acids of interest in this study can be successfully separated by LEV via forming enantiospecific co-crystal, but the resolution performance is significantly different. The results showed that LEV selectively co-crystallized with S enantiomers of 2-ClMA, 3-ClMA, 4-ClMA, and 4-BrMA, while it co-crystallized with R enantiomers of 4-FMA. This indicates that the position and type of substituents of racemic compounds not only affect the co-crystal configuration, but also greatly affect the efficiency of co-crystal resolution.
Asunto(s)
Levetiracetam/química , Ácidos Mandélicos/química , Cristalización , Halogenación , Solventes/química , Estereoisomerismo , Temperatura , Factores de TiempoRESUMEN
PURPOSE: Proper taste-masking formulation design is a critical issue for instant-dissolving tablets (IDTs). The purpose of this study is to use the electronic tongue to design the additives of the 3D printed IDTs to improve palatability. METHODS: A binder jet 3D printer was used to prepare IDTs of levetiracetam. A texture analyzer and dissolution apparatus were used to predict the oral dispersion time and in vitro drug release of IDTs, respectively. The palatability of different formulations was investigated using the ASTREE electronic tongue in combination with the design of experiment and a model for masking bitter taste. Human gustatory sensation tests were conducted to further evaluate the credibility of the results. RESULTS: The 3D printed tablets exhibited rapid dispersion (<30 s) and drug release (2.5 min > 90%). The electronic tongue had an excellent ability of taste discrimination, and levetiracetam had a good linear sensing performance based on a partial least square regression analysis. The principal component analysis was used to analyze the signal intensities of different formulations and showed that 2% sucralose and 0.5% spearmint flavoring masked the bitterness well and resembled the taste of corresponding placebo. The results of human gustatory sensation test were consistent with the trend of the electronic tongue evaluation. CONCLUSIONS: Owing to its objectivity and reproducibility, this technique is suitable for the design and evaluation of palatability in 3D printed IDT development.
Asunto(s)
Composición de Medicamentos/instrumentación , Nariz Electrónica , Excipientes/química , Levetiracetam/química , Gusto , Administración Oral , Composición de Medicamentos/métodos , Humanos , Levetiracetam/administración & dosificación , Impresión Tridimensional , Reproducibilidad de los Resultados , ComprimidosRESUMEN
The establishment of 3D-printing as manufacturing process for oral solid dosage forms enables new options for the individualized medicine. The aim of this work was to develop a novel drug-printing model using pressure-assisted microsyringe (PAM) technology, which allows the precise dispensing of drug substances. Printed tablets with different numbers of layers, mimicking different doses for pediatric subgroups, were analyzed regarding mass variation, friability, thickness and disintegration time. Furthermore, the uniformity of dosage units and the dissolution behavior were investigated. Friability was <0.3% in all cases, which demonstrates the ability of PAM printing to manufacture robust solid dosage. Disintegration results showed the dependency of the disintegration on the number of layers and therefore on the compact mass of polymer. However, all tablets disintegrated within 3 min and fulfilled the requirements of immediate release tablets of the USP and orodispersible tablets according to the Ph. Eur. Results of uniformity dosage units confirmed the successful manufacturing of the intended individualized doses. Drug dissolution appeared to be dependent on the number of layers. An increase of layers resulted in a decrease of the drug release rate. Further, the drug release could be correlated to the surface area/volume (SA/V) ratio.
Asunto(s)
Anticonvulsivantes/química , Levetiracetam/química , Microtecnología/instrumentación , Impresión Tridimensional/instrumentación , Jeringas , Tecnología Farmacéutica/instrumentación , Anticonvulsivantes/administración & dosificación , Liberación de Fármacos , Diseño de Equipo , Levetiracetam/administración & dosificación , Miniaturización , Presión , Solubilidad , ComprimidosRESUMEN
A new strategy is developed to design multi-drug solid forms. Using an inorganic salt as the glue sticking together two different APIs in a "drug-bridge-drug" approach, we successfully created and characterized three different ternary ionic cocrystals (TICCs). The link between binary and ternary ICCs and the importance of reaction stoichiometry was investigated using ternary solid-state phase diagrams. In addition, we highlighted the crucial role of water for the stability of these systems, as well as the impact on solubility compared to the respective parent compounds. We expect the strategy presented here to be applicable to a large series of drug combinations, opening up a promising new way of building multi-drug systems.
Asunto(s)
Cloruro de Calcio/química , Levetiracetam/química , Niacinamida/química , Cristalización , Estructura MolecularRESUMEN
BACKGROUND: The clinical value of therapeutic drug monitoring can be increased most significantly by integrating assay results into clinical pharmacokinetic models for optimal dosing. The correct weighting in the modeling process is 1/variance, therefore, knowledge of the standard deviations (SD) of each measured concentration is important. Because bioanalytical methods are heteroscedastic, the concentration-SD relationship must be modeled using assay error equations (AEE). We describe a methodology of establishing AEE's for liquid chromatography-tandem mass spectrometry (LC-MS/MS) drug assays using carbamazepine, fluconazole, lamotrigine and levetiracetam as model analytes. METHODS: Following method validation, three independent experiments were conducted to develop AEE's using various least squares linear or nonlinear, and median-based linear regression techniques. SD's were determined from zero concentration to the high end of the assayed range. In each experiment, precision profiles of 6 ("small" sample sets) or 20 ("large" sample sets) out of 24 independent, spiked specimens were evaluated. Combinatorial calculations were performed to attain the most suitable regression approach. The final AEE's were developed by combining the SD's of the assay results, established in 24 specimens/spiking level and using all spiking levels, into a single precision profile. The effects of gross hyperbilirubinemia, hemolysis and lipemia as laboratory interferences were investigated. RESULTS: Precision profiles were best characterized by linear regression when 20 spiking levels, each having 24 specimens and obtained by performing 3 independent experiments, were combined. Theil's regression with the Siegel estimator was the most consistent and robust in providing acceptable agreement between measured and predicted SD's, including SD's below the lower limit of quantification. CONCLUSIONS: In the framework of precision pharmacotherapy, establishing the AEE of assayed drugs is the responsibility of the therapeutic drug monitoring service. This permits optimal dosages by providing the correct weighting factor of assay results in the development of population and individual pharmacokinetic models.
Asunto(s)
Cromatografía Liquida/métodos , Monitoreo de Drogas/métodos , Modelos Biológicos , Medicina de Precisión/métodos , Espectrometría de Masas en Tándem/métodos , Carbamazepina/química , Exactitud de los Datos , Fluconazol/química , Humanos , Lamotrigina/química , Análisis de los Mínimos Cuadrados , Levetiracetam/química , Límite de Detección , Concentración Osmolar , Suero/química , Programas InformáticosRESUMEN
Communicated by Ramaswamy H. Sarma.
Asunto(s)
ADN/química , Compuestos de Hierro/química , Levetiracetam/química , Nanopartículas de Magnetita/química , Albúmina Sérica Humana/química , Dióxido de Silicio/química , Adsorción , Técnicas de Química Sintética , Humanos , Cinética , Levetiracetam/administración & dosificación , Levetiracetam/farmacocinética , Nanopartículas de Magnetita/ultraestructura , Modelos Anatómicos , Conformación Molecular , Estructura Molecular , Unión Proteica , Solubilidad , Análisis Espectral , Termodinámica , AguaRESUMEN
In our recent studies, we identified compound N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) as a broad-spectrum hybrid anticonvulsant which showed potent protection across the most important animal acute seizure models such as the maximal electroshock (MES) test, the subcutaneous pentylenetetrazole (s.c. PTZ) test, and the 6-Hz (32 mA) test in mice. Therefore, AS-1 may be recognized as a candidate for new anticonvulsant effective in different types of human epilepsy with a favorable safety margin profile determined in the rotarod test in mice. In the aim of further pharmacological evaluation of AS-1, in the current study, we examined its activity in the 6-Hz (44 mA) test, which is known as the model of drug-resistant epilepsy. Furthermore, we determined also the antiseizure activity in the kindling model of epilepsy induced by repeated injection of pentylenetetrazole (PTZ) in mice. As a result, AS-1 revealed relatively potent protection in the 6-Hz (44 mA) test, as well as delayed the progression of kindling induced by repeated injection of PTZ in mice at doses of 15 mg/kg, 30 mg/kg, and 60 mg/kg. Importantly, the isobolographic analysis showed that a combination of AS-1 and valproic acid (VPA) at the fixed ratio of 1:1 displayed a supra-additive (synergistic) interaction against PTZ-induced seizures in mice. Thus, AS-1 may be potentially used in an add-on therapy with VPA. Moreover, incubation of zebrafish larvae with AS-1 substantially decreased the number, cumulative but not the mean duration of epileptiform-like events in electroencephalographic assay. Finally, the in vitro ADME-Tox studies revealed that AS-1 is characterized by a very good permeability in the parallel artificial membrane permeability assay test, excellent metabolic stability on human liver microsomes (HLMs), no significant influence on CYP3A4/CYP2D6 activity, and moderate inhibition of CYP2C9 in a concentration of 10 µM, as well as no hepatotoxic properties in HepG2 cells (concentration of 10 µM).
Asunto(s)
Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/química , Epilepsia/tratamiento farmacológico , Convulsiones/tratamiento farmacológico , Animales , Conducta Animal/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Epilepsia/inducido químicamente , Etosuximida/química , Lacosamida/química , Levetiracetam/química , Masculino , Ratones , Pentilenotetrazol/administración & dosificación , Pirrolidinas/administración & dosificación , Pirrolidinas/química , Convulsiones/inducido químicamente , Ácido Valproico/administración & dosificación , Pez CebraRESUMEN
PURPOSE: Status epilepticus (SE) is characterized by recurrent seizure activity and can be drug- resistant. Knowledge of neuronal and metabolic activity of the brain during SE may be helpful to improve medical care. We here report the effects of three anti-seizure drugs on changes of acetylcholine energy metabolites and oxidative stress during SE. METHODS: We used the lithium-pilocarpine model in rats to induce SE and in vivo- microdialysis to monitor cholinergic and metabolic activity in the hippocampus. We measured extracellular concentrations of acetylcholine, glucose, lactate, pyruvate, glycerol and isoprostanes before and during SE, and after acute treatment with pregabalin, valproic acid, and levetiracteam. RESULTS: Upon onset of SE, acetylcholine (ACh) release increased six- to eightfold. Glucose was increased only transiently by 30% but lactate levels rose four-fold, and extracellular concentrations of glycerol ten-fold. Isoprostanes are markers of oxidative stress and increased more than 20-fold. Two hours after pilocarpine adminstration, rats were treated with pregabalin (100 mg/kg), levetiracetam (200 mg/kg) or valproic acid (400 mg/kg) by i.p. injection. All three drugs stopped seizure activity in a delayed fashion, but at the doses indicated, only animals that received levetiracetam reached consciousness. All drugs reduced ACh release within 60-120 minutes. Lactate/pyruvate ratios, glycerol and isoprostanne levels were also reduced significantly after drug administration. CONCLUSIONS: Hippocampal ACh release closely follows seizure activity in SE and is attenuated when SE subsides. Pregabalin, valproic acid and levetiracetam all terminate seizures in the rat SE model and attenuate cholinergic and metabolic changes within two hours.
Asunto(s)
Anticonvulsivantes/farmacología , Colinérgicos/farmacología , Convulsiones/tratamiento farmacológico , Estado Epiléptico/tratamiento farmacológico , Acetilcolina/análisis , Animales , Anticonvulsivantes/química , Anticonvulsivantes/metabolismo , Conducta Animal , Colinérgicos/química , Colinérgicos/metabolismo , Cromatografía Líquida de Alta Presión , Modelos Animales de Enfermedad , Levetiracetam/química , Levetiracetam/metabolismo , Levetiracetam/farmacología , Masculino , Estrés Oxidativo/efectos de los fármacos , Pregabalina/química , Pregabalina/metabolismo , Pregabalina/farmacología , Ratas , Ratas Sprague-Dawley , Ácido Valproico/química , Ácido Valproico/metabolismo , Ácido Valproico/farmacologíaRESUMEN
A simple and highly sensitive ultra-high-performance liquid chromatographic-diode array (UHPLC-DAD) detection method was developed and validated for the simultaneous estimation of levetiracetam (LEV) and lacosamide (LAC). It was clinically proven that the combination of LEV and LAC exhibits a synergistic effect against refractory seizures in mice, which was the motivation for the analysis of this binary mixture both in bulk and in human urine samples. The binary mixture was resolved on a Hypersil BDS C18 analytical column, utilizing a mobile phase of 0.050 mol L-1 phosphate buffer (pH 5.60), methanol and acetonitrile in the ratio (80:10:10 v/v/v) using catechol as an internal standard. The mobile phase was pumped at a flow rate of 1.2 mL min-1 with diode array detection at 205 nm for both drugs and 270 nm for IS. Calibration curves were linear with correlation coefficient >0.9990 over the studied concentration range of 0.1-70.0 µg mL-1 for both drugs. The developed method was reproducible with low relative standard deviation values for intra- and inter-day precision (<2.0%). Both drugs were determined in bulk, pharmaceutical formulations and human urine samples without any interference from complex matrices.
Asunto(s)
Anticonvulsivantes/orina , Cromatografía Líquida de Alta Presión/métodos , Lacosamida/orina , Levetiracetam/orina , Adulto , Anticonvulsivantes/química , Anticonvulsivantes/farmacocinética , Sinergismo Farmacológico , Femenino , Humanos , Lacosamida/química , Lacosamida/farmacocinética , Levetiracetam/química , Levetiracetam/farmacocinética , Límite de Detección , Modelos Lineales , Reproducibilidad de los ResultadosRESUMEN
A comprehensive profile of levetiracetam is presented in this chapter which includes its description, formula, elemental analysis, appearance, uses and applications. Different earlier studies included for example methods of synthesis are described with its typical structural schemes. The profile also listed the drug's physical characteristics indicating its solubility, X-ray powder diffraction pattern, thermal methods of analysis as well as its spectroscopic characteristics. Different methods of analysis which includes compendial method of analysis, as well as reported method of analysis which include spectrophotometry, spectrofluorometry, electrochemical method, chromatographic method, and immunoassay method of analysis. The study was include drug stability, clinical pharmacology, e.g., mechanism of action, pharmacokinetic study. Around 70 references are recorded as a proof of this chapter.
Asunto(s)
Levetiracetam/farmacología , Estabilidad de Medicamentos , Levetiracetam/químicaRESUMEN
Total synthesis of levetiracetam, an active ingredient of epilepsy treatment medications, is reported. The reported method is based on a one-pot dehydration/sigmatropic rearrangement of (R,E)-hept-4-en-3-ol carbamate to the corresponding allylamine derivative, an advanced precursor of levetiracetam.
Asunto(s)
Anticonvulsivantes/síntesis química , Levetiracetam/síntesis química , Anticonvulsivantes/química , Carbamatos/química , Técnicas de Química Sintética , Levetiracetam/químicaRESUMEN
Continuous-flow production of chiral intermediates plays an important role in the development of building blocks for Active Pharmaceutical Ingredients (APIs), being α-amino acids and their derivatives widely applied as building blocks. In this work we developed two different strategies for the synthesis of intermediates used on the synthesis of levetiracetam/brivaracetam and ethambutol. The results obtained show that methionine methyl ester can be continuously converted to the desired ethambutol intermediate by RANEY® Nickel dessulfurization/reduction strategy whereas levetiracetam/brivaracetam intermediates could be synthesized by both RANEY® Nickel (without H2) and Pd/C-H2 approach or by photochemical desulfurization.
Asunto(s)
Anticonvulsivantes/síntesis química , Anticonvulsivantes/farmacología , Antituberculosos/síntesis química , Antituberculosos/farmacología , Anticonvulsivantes/química , Antituberculosos/química , Técnicas de Química Sintética , Etambutol/síntesis química , Etambutol/química , Etambutol/farmacología , Levetiracetam/síntesis química , Levetiracetam/química , Levetiracetam/farmacología , Pirrolidinonas/síntesis química , Pirrolidinonas/química , Pirrolidinonas/farmacología , Estereoisomerismo , Azufre/químicaRESUMEN
Recently, transdermal reverse iontophoresis across the skin has been investigated as a novel technology for the purpose of diagnosis as well as therapeutic drug monitoring. Accordingly, the objective of this study was to investigate ex vivo and in vivo transdermal extraction of levetiracetam, an antiepileptic drug, across the pig ear skin by reverse iontophoresis. Reverse iontophoresis experiments were performed using three chambered diffusion cells. Extractions profiles were generated in phosphate buffers at different current intensities, pH and ionic strength as well donor drug concentrations. This was followed by ex vivo extraction in gels and in vivo extractions using New Zealand rabbits. Results indicate that levetiracetam was extracted at both anode and cathode. Flux values were unaffected by increase in current intensities (0.5â¯mA and 0.6â¯mA) but affected by pH and ionic strength. Neither in cathodal nor in anodal extraction, flux values did show a proportional relationship with the donor drug concentration. At low and medium concentration levels, flux values did not show any major change but the extraction flux at high donor concentration was much higher. In contrast, in vivo experiment with rabbits resulted in wide variation of fluxes with very high fluxes recorded at the cathodal end. Reasons attributed to this difference may include lower current intensity, and species variation. The most significant finding of this study is that measurable amounts of the levetiracetam were extracted at both the ends indicating its feasibility for non-invasive drug monitoring.
Asunto(s)
Monitoreo de Drogas/métodos , Iontoforesis/métodos , Levetiracetam/química , Animales , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/sangre , Anticonvulsivantes/química , Anticonvulsivantes/farmacocinética , Relación Dosis-Respuesta a Droga , Geles , Humanos , Levetiracetam/administración & dosificación , Levetiracetam/sangre , Levetiracetam/farmacocinética , ConejosRESUMEN
Levetiracetam therapy is often associated with high levels of individual variation in the recommended dose required to achieve preferential treatment. Thus, a reliable and dynamic regulation system to accurately tailor dose is necessary. The main objective of this study is to explore and prepare a dose-flexible control system suitable for rapid release tablets equipped with high drug loading and a cylindrical model design. Semi-solid extrusion 3-dimensional printing was utilized to fabricate a series of tablets of increased volume. This method was compatible with 3 patterns to regulate the volumes to manipulate the tablet mass and achieve tailored personalized precision dosing. All tablets from each pattern exhibited a smooth surface and regular shape, as well as sufficient mechanical strength. A good linear correlation between the mass and theoretical volume of the tablets was maintained, regardless of the pattern used. The range of dose accuracy was between 103.3% and 96.2%, with an acceptable variation coefficient in the range of 0.6%-3.2%. Faster release behavior for levetiracetam can be achieved from the small-sized tablets due to their larger surface area/mass ratio. All the results demonstrated the potential and capability of semi-solid extrusion 3-dimensional printing as a novel pharmaceutical manufacturing technique to provide a dynamic and highly accurate controllable system for preparing patient-tailored medicines.
Asunto(s)
Anticonvulsivantes/química , Composición de Medicamentos/instrumentación , Levetiracetam/química , Impresión Tridimensional , Anticonvulsivantes/administración & dosificación , Liberación de Fármacos , Levetiracetam/administración & dosificación , Solubilidad , Comprimidos , Resistencia a la TracciónRESUMEN
Fast and accurate manufacturing of individually tailored solid dosage forms is one of the main challenges for personalized medicine. The use of 3D printers has recently been studied to determine their suitability for personalized drug manufacturing. In the current work, formulations free of organic solvents were developed for a pressure-assisted microsyringe printing method (PAM). The water soluble polymer polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG) was used as matrix, while levetiracetam (LEV) was used as model drug. Furthermore, the influence of a second polymer, polyvinylpyrrolidone-vinyl acetate copolymer (PVP-PVAc) on the properties of the printed tablets was investigated. Tablets were printed using a 3D-Bioplotter. The printed formulations were analyzed regarding mass variation, friability and thickness. Furthermore, the disintegration behavior and dissolution profile were analyzed. Investigations of the dissolution profiles of printed tablets show that an immediate release of the API could be achieved. For tablets with PVA-PEG the drug is released completely within 10â¯min while the additional use of PVP-PVAc leads to a slightly delay with a complete release within 20â¯min. The same trend is observed regarding the disintegration time of printed tablets. Tablets with PVA-PEG disintegrated within 95⯱â¯10â¯s while tablets with additional PVP-PVAc disintegrated within 130⯱â¯20â¯s. Friability of <0.5% indicate that the used PAM printing method provides tablets without loss of structural integrity during handling. Furthermore, it could be shown that the production of tablets with a good content uniformity using a 3D Bioplotter is suitable.
Asunto(s)
Composición de Medicamentos/métodos , Liberación de Fármacos , Microtecnología/instrumentación , Impresión Tridimensional/instrumentación , Rastreo Diferencial de Calorimetría/instrumentación , Rastreo Diferencial de Calorimetría/métodos , Cromatografía Líquida de Alta Presión/instrumentación , Cromatografía Líquida de Alta Presión/métodos , Composición de Medicamentos/instrumentación , Excipientes/química , Levetiracetam/química , Microtecnología/métodos , Polivinilos/química , Presión , Jeringas , Comprimidos , Difracción de Rayos X/instrumentación , Difracción de Rayos X/métodosRESUMEN
Selective receptors imaging using gamma emitting radiopharmaceuticals allows accurate diagnosis and follow up of many brain related disorders. Levetiracetam, a selective SV2A receptor antiepileptic, was successfully radiolabeled using 99mTc. Different conditions affecting the labelling process were studied and optimum radiochemical yield of 89.8% was obtained. 99mTc-levetiracetam was effectively formulated and characterized as microemulsion with particle size of 16.34⯱â¯5.58â¯nm and polydispersity index of 0.382⯱â¯0.05. Parallel biodistribution studies were performed comparing brain targeting efficiency of I.V 99mTc-levetiracetam solution, I.N 99mTc-levetiracetam solution and I.N 99mTc-levetiracetam microemulsion. Brain radioactivity uptake and brain/blood uptake ratio for I.N 99mTc-levetiracetam microemulsion were higher than the other two routes at all time intervals. Such results present intranasal 99mTc-levetiracetam microemulsion as the first SPECT tracer for imaging SV2A receptor.